On U.S. market, Innovate Pharmaceuticals (INNT), looking to enter P3 in Celiac's disease, trading at $625,000,000 market cap (25+M shares outstanding). $IMRN entering P3 in NASH, 3.6M shares, $40,000,000 MC.
Reminder of What We Have in IMM-124E, page-2
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.79M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 51067 | 1 |
View Market Depth
| Last trade - 16.12pm 03/10/2024 (20 minute delay) ? |
| IMC (ASX) Chart |
Day chart unavailable